Skip to main content
. 2020 Jul 24;11:3702. doi: 10.1038/s41467-020-17564-z

Fig. 6. Plerixafor (AMD3100) mobilizes HSPCs, rescues extramedullary hematopoiesis, and boosts circulating immune cells after T3 transection SCI.

Fig. 6

a Cytokine and chemokine mRNA expression from whole-bone marrow cells of SCI mice 3 dpi (expressed as fold change of Lam). b CXCL12 protein expression from bone marrow extracellular fluid extracts. c Protein expression (MFI) of CXCR4 expression on LSKs from whole bone marrow. d Total CFCs per mL whole blood, e CFCs per spleen, f LSKs per spleen, g c-Kit+ HSPCs per spleen, and h total cells per spleen 3 days after SCI with and without daily AMD3100 treatment (once per day). i Total white blood cells (WBCs), lymphocytes, neutrophils, and monocytes per mL whole blood. j Proportion of monocytes (MO), lymphocytes (LY), and neutrophils (NE) in whole blood (n = 5/group). k Total cells per femur. All data are mean ± SEM, two-sample t-test; n = 3/group (pooled) in a; n = 6 and 7/group in b; n = 7/group in c; n = 5/group in d–k. Dotted lines represent average data from lam (a) or naïve mice (d, e, h, i, k). BM bone marrow, MFI mean fluorescence intensity, WBCs white blood cells, MO monocytes, LY lymphocytes, NE neutrophils, AMD Plerixafor (AMD3100). Source data are provided as a Source Data file.